<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37790297</PMID><DateRevised><Year>2024</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2693-5015</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Sep</Month><Day>20</Day></PubDate></JournalIssue><Title>Research square</Title><ISOAbbreviation>Res Sq</ISOAbbreviation></Journal><ArticleTitle>Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">rs.3.rs-3359429</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.21203/rs.3.rs-3359429/v1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Prior case series suggest that a 5-day course of oral Paxlovid (nirmatrelvir/ritonavir) benefits some people with Long COVID, within and/or outside of the context of an acute reinfection. To the best of our knowledge, there have been no prior case series of people with Long COVID who have attempted longer courses of nirmatrelvir/ritonavir.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We documented a case series of 13 individuals with Long COVID who initiated extended courses (&gt;5 days; range: 7.5-30 days) of oral nirmatrelvir/ritonavir outside (n=11) of and within (n=2) the context of an acute SARS-CoV-2 infection. Participants reported on symptoms and health experiences before, during, and after their use of nirmatrelvir/ritonavir.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Among those who took a long course of nirmatrelvir/ritonavir outside of the context of an acute infection, some experienced a meaningful reduction in symptoms, although not all benefits persisted; others experienced no effect on symptoms. One participant reported intense stomach pain that precluded her from continuing her course. Among the two participants who took a long course of nirmatrelvir/ritonavir within the context of an acute reinfection, both eventually returned to their pre-re-infection baseline.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">Long courses of nirmatrelvir/ritonavir may have meaningful benefits for some people with Long COVID but not others. We encourage researchers to study who, how, and why nirmatrelvir/ritonavir benefits some and what course length is most effective, with the goal of informing clinical recommendations for using nirmatrelvir/ritonavir and/or other antivirals as a potential treatment for Long COVID.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Alison K</ForeName><Initials>AK</Initials><Identifier Source="ORCID">0000-0001-9848-934X</Identifier><AffiliationInfo><Affiliation>University of California San Francisco &amp; Patient-Led Research Collaborative.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaudon</LastName><ForeName>Toni Wall</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Patient-Led Research Collaborative &amp; University of Arkansas for Medical Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schurman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Kava</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Patient-Led Research Collaborative.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Julia Moore</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Scripps Research Translational Institute and Patient-Led Research Collaborative.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haas-Godsil</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Patient-Led Research Collaborative.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crausman</LastName><ForeName>Samantha</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Leslie</LastName><ForeName>Kate</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Bligh</LastName><ForeName>Siobhan Christine</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Lizars</LastName><ForeName>Gillian</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Davids</LastName><ForeName>J D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Sran</LastName><ForeName>Saniya</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Peluso</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-0585-6230</Identifier><AffiliationInfo><Affiliation>University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCorkell</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-3261-6737</Identifier><AffiliationInfo><Affiliation>Patient-Led Research Collaborative.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 AI157875</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AI147159</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Res Sq</MedlineTA><NlmUniqueID>101768035</NlmUniqueID><ISSNLinking>2693-5015</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">case series</Keyword><Keyword MajorTopicYN="N">nirmatrelvir/ritonavir (Paxlovid)</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of SARS-CoV-2 (PASC)</Keyword></KeywordList><CoiStatement>Conflicts of interest to declare: Dr. Peluso has served as a consultant for Gilead Sciences and AstraZeneca, outside the submitted work. The remaining authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>4</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37790297</ArticleId><ArticleId IdType="pmc">PMC10543503</ArticleId><ArticleId IdType="doi">10.21203/rs.3.rs-3359429/v1</ArticleId><ArticleId IdType="pii">rs.3.rs-3359429</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nat Rev Immunol. Published online July 11, 2023. doi:10.1038/s41577-023-00904-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-023-00904-7</ArticleId><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;146. doi:10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Coronavirus (COVID-19) Dashboard. Accessed August 23, 2023. https://covid19.who.int</Citation></Reference><Reference><Citation>Ballering AV, van Zon SKR, olde Hartman TC, Rosmalen JGM. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. The Lancet. 2022;400(10350):452&#x2013;461. doi:10.1016/S0140-6736(22)01214-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford ND. Long COVID and Significant Activity Limitation Among Adults, by Age &#x2014; United States, June 1&#x2013;13, 2022, to June 7&#x2013;19, 2023. MMWR Morb Mortal Wkly Rep. 2023;72. doi:10.15585/mmwr.mm7232a3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7232a3</ArticleId><ArticleId IdType="pmc">PMC10415000</ArticleId><ArticleId IdType="pubmed">37561665</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T, Jolley SE, Karlson EW, et al. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA. 2023;329(22):1934&#x2013;1946. doi:10.1001/jama.2023.8823</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.8823</ArticleId><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. eClinicalMedicine. 2021;38. doi:10.1016/j.eclinm.2021.101019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae. Clin Infect Dis. 2023;76(3):e487&#x2013;e490. doi:10.1093/cid/ciac722</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac722</ArticleId><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Liotti FM, Menchinelli G, Marchetti S, et al. Assessment of SARS-CoV-2 RNA Test Results Among Patients Who Recovered From COVID-19 With Prior Negative Results. JAMA Intern Med. 2021;181(5):702&#x2013;704. doi:10.1001/jamainternmed.2020.7570</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.7570</ArticleId><ArticleId IdType="pmc">PMC7662488</ArticleId><ArticleId IdType="pubmed">33180119</ArticleId></ArticleIdList></Reference><Reference><Citation>Vibholm LK, Nielsen SSF, Pahus MH, et al. SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses. EBioMedicine. 2021;64:103230. doi:10.1016/j.ebiom.2021.103230</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103230</ArticleId><ArticleId IdType="pmc">PMC7847186</ArticleId><ArticleId IdType="pubmed">33530000</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Xiao J, Sun R, et al. Prolonged Persistence of SARS-CoV-2 RNA in Body Fluids - Volume 26, Number 8&#x2014;August 2020. - Emerging Infectious Diseases journal - CDC. doi:10.3201/eid2608.201097</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2608.201097</ArticleId><ArticleId IdType="pmc">PMC7392422</ArticleId><ArticleId IdType="pubmed">32383638</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB, Aleman S, et al. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). Nat Immunol. Published online September 4, 2023. doi:10.1038/s41590-023-01601-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01601-2</ArticleId><ArticleId IdType="pubmed">37667052</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Front Microbiol. 2021;12. 10.3389/fmicb.2021.698169</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhao D, Liu X, Chen X, Xiao W, Feng L. Early administration of Paxlovid reduces the viral elimination time in patients infected with SARS-CoV-2 Omicron variants. J Med Virol. 2023;95(1):e28443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9880690</ArticleId><ArticleId IdType="pubmed">36579782</ArticleId></ArticleIdList></Reference><Reference><Citation>Niraj N, Mahajan SS, Prakash A, Sarma P, Medhi B. Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era. Indian J Pharmacol. 2022;54(6):452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10043822</ArticleId><ArticleId IdType="pubmed">36722557</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post&#x2013;COVID-19 condition. JAMA Intern Med. 2023;183(6):554&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Anglin K, Durstenfeld MS, et al. Effect of oral nirmatrelvir on long COVID symptoms: 4 cases and rationale for systematic studies. Pathog Immun. 2022;7(1):95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9254867</ArticleId><ArticleId IdType="pubmed">35800257</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng LN, Bonilla HF, Shafer RW, Miglis MG, Yang PC. Case report of breakthrough long COVID and the use of nirmatrelvir-ritonavir. Published online 2022.</Citation></Reference><Reference><Citation>IOM
2015 Diagnostic Criteria | Diagnosis | Healthcare Providers | Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) | CDC. Published April 27, 2021. Accessed August 24, 2023. https://www.cdc.gov/me-cfs/healthcare-providers/diagnosis/iom-2015-diagnostic-criteria.html</Citation></Reference><Reference><Citation>Carruthers BM, van de Sande MI, De Meirleir KL, et al. Myalgic encephalomyelitis: international consensus criteria. J Intern Med. 2011;270(4):327&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3427890</ArticleId><ArticleId IdType="pubmed">21777306</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HG, Honerlaw JP, Maripuri M, et al. Potential pitfalls in the use of real-world data for studying long COVID. Nat Med. Published online 2023:1&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10205658</ArticleId><ArticleId IdType="pubmed">37055567</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>